Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study.

JCO precision oncology·2026
Same author

Clinical Applications of Liquid Biopsy in Colorectal Cancer: A Focus on Registered Clinical Trials.

Genes·2026
Same author

Distinct protein and metabolic profiles in patients with advanced clear-cell renal cell carcinoma treated with sunitinib: a study of the Spanish oncology genitourinary group.

Frontiers in oncology·2026
Same author

3D Glioblastoma Molecular Responses to Carbon Dot-Delivered Riluzole Probed by Synchrotron FTIR.

Analytical chemistry·2026
Same author

Isolation and characterization of extracellular vesicles from human milk for potential use as a dietary supplement in clinical research with preterm infants.

Frontiers in nutrition·2026
Same author

Correction to: Incidence and survival among children with neuroblastoma in Spain over 22 years.

BMC cancer·2026

Related Experiment Video

Updated: Jan 2, 2026

On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis
06:48

On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis

Published on: May 31, 2020

6.2K

Metabolomic profiling in neuroblastoma.

Guillermo Quintás1,2, Yania Yáñez3, Pablo Gargallo3

  • 1Leitat Technological Center, Health and Biomedicine Division, Barcelona, Spain.

Pediatric Blood & Cancer
|December 6, 2019
PubMed
Summary

Metabolomic analysis of plasma samples can improve risk stratification and outcome prediction for neuroblastoma (NB), a challenging childhood cancer. This noninvasive approach identified distinct metabolic profiles, aiding in early detection and prognosis.

Keywords:
biomarkerchildhood neuroblastomametabolomeprognosisrisk stratification

More Related Videos

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening
06:50

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening

Published on: September 5, 2025

364
Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
11:02

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics

Published on: November 29, 2024

991

Related Experiment Videos

Last Updated: Jan 2, 2026

On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis
06:48

On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis

Published on: May 31, 2020

6.2K
Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening
06:50

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening

Published on: September 5, 2025

364
Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
11:02

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics

Published on: November 29, 2024

991

Area of Science:

  • Biochemistry
  • Oncology
  • Biomarker Discovery

Background:

  • Neuroblastoma (NB) is a significant cause of childhood cancer mortality.
  • Current risk-based treatments improve outcomes but survival for high-risk patients remains poor.
  • Metabolomics offers a noninvasive approach for cancer screening, outcome prediction, and treatment assessment.

Purpose of the Study:

  • To evaluate the utility of plasma metabolomics for enhancing risk-group stratification in NB.
  • To assess the potential of metabolomic profiling for improving outcome prediction in NB patients.
  • To identify metabolic signatures associated with disease progression and treatment response.

Main Methods:

  • Plasma samples were collected from 110 NB patients at diagnosis and end of treatment.
  • Ultra-performance liquid chromatography-time of flight mass spectrometry (UPLC-MS) was used for metabolomic analysis.
  • A metabolomic model was developed and validated on an external dataset.

Main Results:

  • Distinct plasma metabolic profiles differentiated high-risk from low-risk NB patients at diagnosis.
  • The metabolomic model achieved 84.2% sensitivity and 93.7% specificity in external validation.
  • Metabolomic profiling distinguished high-risk patients with active disease from those in remission and identified a subset who progressed.

Conclusions:

  • Plasma metabolomics shows promise for improving NB risk stratification and outcome prediction.
  • This study represents the largest investigation into the prognostic power of plasma metabolomics in NB.
  • Further validation studies with larger cohorts are recommended to confirm these findings.